Statin use and mortality in rheumatoid arthritis: an incident user cohort study

Abstract

immune function, which lead to increased disability, morbidity, and mortality. [2][3][4] Specifically, patients with RA have been shown to be at a higher risk for comorbidities such as musculoskeletal system diseases, diseases of Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by an inflammatory polyarthritis that preferentially affects the small joints. 1 RA is a "multicausal" disease that most likely results from an amalgamation of genetic predisposition and various environmental and lifestyle factors. Patients with this disease often experience complications, such as cardiovascular disease, systemic inflammation, and impaired

Reduction of Cardiovascular Disease and Mortality Versus Risk of New‐Onset Diabetes Mellitus With Statin Use in Patients With Rheumatoid Arthritis

“…On the other hand, the magnitude of all-cause mortality reduction we found was higher than in studies in the general population (7,8). Although a study of the general population in CPRD showed a 55% all-cause mortality reduction in secondary prevention (38), observational studies in RA patients with incident statin user design showed an approximately 25% reduction in all-cause mortality, which was again less than ours (22,36). This difference compared to the general population may be partly explained by pleiotropic effects of statins.…”

“…Post hoc analyses of 2 statin RCTs (intensive versus moderate statins for secondary prevention) showed a nonsignificant CVD reduction in RA patients (n = 199) compared to patients without inflammatory arthritis (19% versus 20%) (21). The few observational studies that had different study populations (with or without prior CVD), different designs (prevalent or incident statin users, with or without propensity score matching), and different outcomes (composite or individual CVD events, or all-cause mortality) showed a significant reduction of composite CVD event (approximately 28-55%) (33)(34)(35) and all-cause mortality (21-57%) (22,(34)(35)(36) with statin use for primary prevention. However, statin use for secondary prevention was not found to be associated with significant CVD and all-cause mortality reductions (34,35).…”

Identification of subgroups within a Japanese older adult population for whom statin therapy is effective in reducing mortality

“…Several observational studies demonstrated that statin therapy reduced all-cause mortality in patients with rheumatic diseases [40][41][42], consistent with the results of the present study. Statins were also found to reduce the risk of all-cause mortality in a population with dementia [43].…”

Effect of Statins on All-Cause Mortality in Adults: A Systematic Review and Meta-Analysis of Propensity Score-Matched Studies

“…A total of 665 citations were identified, and 210 potentially eligible articles were retrieved in full text. Overall, 54 studies were included in the review ( Figure 1 ) [ 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 ]. Risk of bias assessment using NOS showed that the studies have low risk of bias.…”